Related references
Note: Only part of the references are listed.A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2017)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
Jordi Rodon et al.
EUROPEAN JOURNAL OF CANCER (2017)
Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
J. Goldman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
Lyudmila Bazhenova et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
Natasha B. Leighl et al.
ONCOTARGET (2017)
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
Phase 1/2 Study of Rilotumumab (AMG 102), a Hepatocyte Growth Factor Inhibitor, and Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Ahmad A. Tarhini et al.
CANCER (2017)
Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors
Kohei Shitara et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors
Sheri L. Moores et al.
CANCER RESEARCH (2016)
A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance
Ling Liu et al.
CANCER RESEARCH (2016)
Referral practices of medical oncologists to palliative care for patients with metastatic non-small cell lung cancer (NSCLC).
Emily Feld et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
Tony Shu Kam Mok et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Joel W. Neal et al.
LANCET ONCOLOGY (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
Sa Ye et al.
SCIENTIFIC REPORTS (2016)
P7.02 * The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis
V. Hanssens et al.
ANNALS OF ONCOLOGY (2015)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
Jong Kyu Woo et al.
ONCOTARGET (2015)
The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
Coumaran Egile et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC
Celina D'Cruz et al.
CANCER RESEARCH (2014)
LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Ling Liu et al.
CLINICAL CANCER RESEARCH (2014)
Effect of Onartuzumab Added to Erlotinib on Metastasis in Patients With Lung Cancer Reply
David Robert Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Friedhelm Bladt et al.
CANCERS (2014)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line
Yong Yook Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
Structural insights into Met receptor activation
Hartmut H. Niemann
EUROPEAN JOURNAL OF CELL BIOLOGY (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2010)
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Michael S. Gordon et al.
CLINICAL CANCER RESEARCH (2010)
Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
Giovanni Pacchiana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
S. F. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status
Takamitsu Onitsuka et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
Wataru Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer models
Kristan A. Meetze et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
Stephanie Kermorgant et al.
JOURNAL OF CELL BIOLOGY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
c-Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis
Yu Nakamura et al.
CANCER SCIENCE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
A Petrelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen et al.
CANCER LETTERS (2005)
Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
PC Ma et al.
CANCER RESEARCH (2005)
How to make tubes:: signaling by the Met receptor tyrosine kinase
M Rosário et al.
TRENDS IN CELL BIOLOGY (2003)
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase
CR Maroun et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses
U Schaeper et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
